Cost of sales for Q3 2024 increased to $29,100,000 reflecting the sales of NERLYNX to grow our China partner and includes $2,400,000 for the amortization of intangible assets related to our neratinib license. Cost of sales for Q2 2024 was $10,700,000 Going forward, we will continue to recognize amortization of the milestones to the licensor about $2,400,000 per quarter as cost of sales. For fiscal year 2024, Puma anticipate that net products revenue for NERLYNX will be in the range of $187,000,000 to $190,000,000 We also anticipate that our gross to net adjustment for the full year 2024 will be between 20.5% 21.5%, higher than 2023 due to the impact of the Inflation Reduction Act, unexpected Medicaid rebates. In addition, for fiscal year 2024, we anticipate receiving royalties from our partners around the world in the range of $34,000,000 to $36,000,000 We expect license revenue in 2024 in the range of $1,000,000 to $2,000,000 We also expect our net income for the full year will be in the range of $15,000,000 to $17,000,000 We anticipate that for Q4 2024, NERLYNX net product revenue will be in the range of $46,000,000 to $48,000,000 We expect Q4 royalties revenues will be in the range of $3,500,000 to $5,000,000 and we anticipate $1,000,000 to $2,000,000 of license revenue.